Sugi Predict

Sugi Predict / Compounds / SCHEMBL672629

SCHEMBL672629

SCHEMBL672629

NC(=O)C(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.69
▸ MAPT P10636 6/20 0.56
▸ HTT P42858 5/20 0.56
▸ ALDH1A1 P00352 4/20 0.56
▸ TSHR P16473 3/20 0.53
▸ GAA P10253 2/20 0.53
▸ HPGD P15428 1/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ MEN1 O00255 5/20 0.50
▸ KMT2A Q03164 5/20 0.50
▸ CA12 O43570 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ RAB9A P51151 4/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ LMNA P02545 2/20 0.48
▸ EPHX1 P07099 2/20 0.48
▸ NLRP3 Q96P20 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21568080 0.86 NPC1 (0.67) NPC1MAPTHTTALDH1A1TSHR
SCHEMBL224279 0.82 NPC1 (1.00) NPC1MAPTHTTALDH1A1TSHR
SCHEMBL9378918 0.81 ALDH1A1 (0.68) NPC1MAPTHTTALDH1A1TSHR
SCHEMBL208060 0.80 CYP19A1 (0.63) NPC1ALDH1A1TSHRMEN1KMT2A
SCHEMBL7126108 0.80 PEPD (0.68) NPC1MAPTALDH1A1TSHRGAA
Hydrochloric Acid SCHEMBL28052562 0.80 NPC1 (0.95) NPC1MAPTHTTALDH1A1TSHR
SCHEMBL26887849 0.79 PTGS2 (0.58) NPC1MAPTHTTALDH1A1GAA
SCHEMBL1504319 0.78 CYP19A1 (0.61) NPC1ALDH1A1TSHRMEN1KMT2A
SCHEMBL12597618 0.78 KDM4E (0.68) NPC1MAPTHTTALDH1A1MEN1
SCHEMBL5433635 0.78 ALDH1A1 (0.59) NPC1MAPTHTTALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993117-B2 Devices with multiple surface functionality THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2015-03-31 — — US claimed
US-20120121661-A1 DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2012-05-17 — — US claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed
CN-115477659-B Edison (R) sarban intermediate compounds 山东新时代药业有限公司 2026-03-17 — — CN disclosed
EP-4382109-A1 USE OF A COMPOSITE MATERIAL Heraeus Medical GmbH (DE) 2024-06-12 — — EP disclosed
US-20240074995-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FIRST WAVE BIO, INC. 2024-03-07 — — US disclosed
US-11793777-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FIRST WAVE BIO, INC. (US) 2023-10-24 — — US disclosed
US-11744812-B2 Methods of treatment FIRST WAVE BIO, INC. (US) 2023-09-05 — — US disclosed
US-20230201143-A1 METHODS OF TREATMENT FIRST WAVE BIO, INC. 2023-06-29 — — US disclosed
WO-2023118074-A1 COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA UNIVERZA V LJUBLJANI (SI) 2023-06-29 — — WO disclosed
US-20230190684-A1 METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND FIRST WAVE BIO, INC. 2023-06-22 — — US disclosed
WO-1995022655-A1 DENSIFYING AGENTS FOR ENHANCING FIBER DENSIFICATION WEYERHAEUSER COMPANY (US) 1995-08-24 — — WO disclosed
EP-0655971-A4 PARTICLE BINDERS. WEYERHAEUSER CO (US) 1995-07-19 — — EP disclosed
EP-0655970-A4 PARTICLE BINDING TO FIBERS. WEYERHAEUSER CO (US) 1995-07-19 — — EP disclosed
EP-0655971-A1 PARTICLE BINDERS WEYERHAEUSER COMPANY (US) 1995-06-07 — — EP disclosed
EP-0655970-A1 PARTICLE BINDING TO FIBERS WEYERHAEUSER COMPANY (US) 1995-06-07 — — EP disclosed
WO-1994004352-A1 PARTICLE BINDERS WEYERHAEUSER COMPANY (US) 1994-03-03 — — WO disclosed
WO-1994004351-A1 PARTICLE BINDING TO FIBERS WEYERHAEUSER COMPANY (US) 1994-03-03 — — WO disclosed
EP-0007719-A2 Cyanbenzofuran derivatives, processes for their preparation and their use in herbicidal compositions; cyanobenzene, benzodioxepine, benzodioxaphosphepine and benzodioxathiepine derivatives FBC LIMITED (GB) 1980-02-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240074995-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 NPC1 2192/4885MAPT 954/4885HTT 778/4885
US-20230190684-A1 METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND ACE2, ACE, MME NPC1 1467/4885MAPT 704/4885HTT 335/4885
US-11744812-B2 Methods of treatment ACE2, ACE, SI NPC1 1662/4885MAPT 845/4885HTT 326/4885
US-20230201143-A1 METHODS OF TREATMENT ACE2, ACE, SI NPC1 1995/4885MAPT 753/4885HTT 346/4885
US-20120121661-A1 DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY PHOSPHO1, CD44, SELP NPC1 4499/4885MAPT 4354/4885HTT 4768/4885
US-11793777-B2 Methods and compositions for treating conditions associated with an abnormal inflammatory response FH, CS, ECHS1 NPC1 2396/4885MAPT 971/4885HTT 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.